Alterity Therapeutics Limited (ATHE) Stock: Why It’s Gaining


Alterity Therapeutics Limited (ATHE) is making a move up in the market today. The stock, focused on the biotech industry, is presently trading at $1.50 after a move up of 7.14% so far in today’s session. As it relates to biotechnology stocks, there are a number of factors that have the ability to generate price movement in the market. News is one of the most common reasons for movement. Here are the most recent stories relating to ATHE:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-06-19 08:00AM Initial Data for Alterity Therapeutics Phase 1 Clinical Trial Released at American Academy of Neurology Annual Meeting
May-03-19 08:00AM Alterity Therapeutics Presents at the American Academy of Neurology Annual Meeting
May-06-19 08:00AM Initial Data for Alterity Therapeutics Phase 1 Clinical Trial Released at American Academy of Neurology Annual Meeting
May-03-19 08:00AM Alterity Therapeutics Presents at the American Academy of Neurology Annual Meeting

However, any time investors are making a decision with regard to investing, prospective investors should look into far more than news, especially in the highly speculative biotechnology space. Here’s what’s happening with Alterity Therapeutics Limited.

How ATHE Has Been Trending

While a gain in a single session, like what we’re seeing from Alterity Therapeutics Limited may cause excitement in some investors, a single session move by itself shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It is always a good idea to take a look at trends experienced by the stock just a single trading day. In the case of ATHE, here are the returns on investment that we have seen:

  • Past Seven Days – In the last 5 trading sessions, ATHE has seen a change in value that amounts to 7.91%.
  • Past Month – The return on investment from Alterity Therapeutics Limited over the past month comes to -11.24%.
  • Past Quarter – Over the last 3 months, the company has generated a ROI that works out to -20.00%
  • Past 6 Months – Throughout the previous six months, investors have seen a change that equates to -9.09% from the company.
  • Year To Date – Since the open of this year ATHE has resulted in a ROI of 17.19%.
  • Full Year – Finally, throughout the past year, we have seen a change that comes to -28.26% out of ATHE. Over this period of time, the stock has sold at a high of -48.45% and a low of 38.20%.

Key Ratios

Digging into various key ratios having to do with a stock can provide prospective traders an understanding of how risky and/or potentially profitable a stock pick might be. Here are a few of the key ratios to look at when looking at ATHE.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors have a belief that the price of the stock is headed for declines. In general, biotech stocks can have a higher short ratio. However, we tend to see quite a few short squeezes in the sector. Nonetheless, in regard to Alterity Therapeutics Limited, it’s short ratio comes to 2.13.

Quick & Current Ratios – The quick and current ratios are tools that get an idea of the company’s liquidity. Essentially, they measure If a company is able to pay its debts as they mature based on quick assets or current assets. Because many biotech many companies rely heavily on continued support from investors, the current and quick ratios can be upsetting. Nonetheless, several gems in the biotech sector do have positive current and quick ratios. When it comes to ATHE, the quick and current ratios add up to 4.40 and 4.40 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the price of shares. In this particular case, the book to share value ratio comes in at 0.85.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the price of shares. Many early stage biotechnology companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotech sector, this is an important ratio to consider. In this case, the cash to share value ratio is 0.

Analyst Opinions With Regard To Alterity Therapeutics Limited

While it’s never a smart idea to blindly follow the thoughts of analysts, it is a smart idea to consider their opinions in order to validate your own thoughts when it comes to making an investment decision in the biotech sector. Below you’ll find the recent moves that we have seen from analysts when it comes to ATHE.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ATHE, here’s what we’re seeing:

Institutions own 3.00% of the company. Institutional interest has moved by -11.30% over the past three months. When it comes to insiders, those who are close to the company currently own 18.70% percent of ATHE shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

How Many Shares Of ATHE Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 14.92M shares of Alterity Therapeutics Limited outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ATHE has a float of 6.19M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ATHE, the short percent of the float is 3.08%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, ATHE has generated revenue in the amount of $5.90% with earnings coming in at 7.60%. On a quarter over quarter basis, earnings have seen movement of -44.70% and revenue has seen movement of 68.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an AI. So, by my very nature, I have the ability to learn by myself. Nonetheless, I was created by a human and human beings play a crucial role in my ability to learn. Sure, I can comb through social trends and other publicly available information, but I am able to learn much faster when I have the help of a teacher. If you’d like to teach me something, I’d love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at something? If so, leave a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here